1.1 Protocol title, protocol identifying number, and date. Any amendment(s) should also bear the amendment number(s) and date(s).
1.2 Name and address of the sponsor and monitor (if other than the sponsor).
1.3 Name and title of the person(s) authorized to sign the protocol and the protocol amendment(s) for the sponsor.
1.4 Name, title, address, and telephone number(s) of the sponsor's medical expert (or dentist when appropriate) for the trial.
1.5 Name and title of the investigator(s) who is (are) responsible for conducting the trial, and the address and telephone number(s) of the trial site(s).
1.6 Name, title, address, and telephone number(s) of the qualified physician (or dentist, if applicable) who is responsible for all trial-site related medical (or dental) decisions (if other than investigator).
1.7 Name(s) and address(es) of the clinical laboratory(ies) and other medical and/or technical department(s) and/or institutions involved in the trial.
2.2 A summary of findings from nonclinical studies that potentially have clinical significance and from clinical trials that are relevant to the trial.
2.3 Summary of the known and potential risks and benefits, if any, to human subjects.
2.4 Description of and justification for the route of administration, dosage, dosage regimen, and treatment period(s).
2.5 A statement that the trial will be conducted in compliance with the protocol, GCP, and the applicable regulatory requirement(s).
2.6 Description of the population to be studied.
2.7 References to literature and data that are relevant to the trial, and that provide background for the trial.
Trial Objectives and Purpose
The scientific integrity of the trial and the credibility of the data from the trial depend ubstantially on the trial design. A description of the trial design should include:
4.1 A specific statement of the primary endpoints and the secondary endpoints, if any, to be measured during the trial.
4.2 A description of the type/design of trial to be conducted (e.g., double-blind, placebo-controlled, parallel design) and a schematic diagram of trial design, procedures, and stages.
4.3 A description of the measures taken to minimize/avoid bias, including (for example):
4.4 A description of the trial treatment(s) and the dosage and dosage regimen of the investigational product(s). Also include a description of the dosage form, packaging, and labeling of the investigational product(s).
4.5 The expected duration of subject participation, and a description of the sequence and duration of all trial periods, including follow-up, if any.
4.6 A description of the "stopping rules" or "discontinuation criteria" for individual subjects, parts of trial, and entire trial.
4.7 Accountability procedures for the investigational product(s), including the placebo(s) and comparator(s), if any.
4.8 Maintenance of trial treatment randomization codes and procedures for breaking codes.
4.9 The identification of any data to be recorded directly on the CRFs (i.e., no prior written or electronic record of data), and to be considered to be source data.
Selection and Exclusion of Subjects
5.2 Subject exclusion criteria.
6.2 Medication(s)/treatment(s) permitted (including rescue medication) and not permitted before and/or during the trial.
6.3 Procedures for monitoring subject compliance.
7.2 Methods and timing for assessing, recording, and analyzing efficacy parameters.
Assessment of Safety
8.2 The methods and timing for assessing, recording, and analyzing safety parameters.
9.2 The type and duration of the follow-up of subjects after adverse events.
10.1 A statement that the sponsor may discontinue study at any time and a description of any actions that may follow such discontinuation of clinical approach.
11.2 The number of subjects planned to be enrolled. In multicenter trials, the number of enrolled subjects projected for each trial site should be specified. Reason for choice of sample size, including reflections on (or calculations of) the power of the trial and clinical justification.
11.3 The level of significance to be used.
11.4 Criteria for the termination of the trial.
11.5 Procedure for accounting for missing, unused, and spurious data.
11.6 Procedures for reporting any deviation(s) from the original statistical plan (any deviation(s) from the original statistical plan should be described and justified in the protocol and/or in the final report, as appropriate).
11.7 The selection of subjects to be included in the analyses (e.g., all randomized subjects, all dosed subjects, all eligible subjects, evaluate-able subjects).
12.1 Drug Accountability: A detailed description of the manner in which clinical supplies will be packaged, including randomization schemes, label contents, coding, etc.
13.1 Informed Consent: Instructions for obtaining legally valid written informed consent from each prospective study patient/subject.
13.2 Subject Withdrawal: A description of the conditions under which patients may withdraw from and/or be withdrawn from the study and procedures for their replacement (if applicable). Subject withdrawal criteria (i.e., terminating investigational product treatment/trial treatment) and procedures specifying:
13.3 Institutional Review Board (IRB): Information concerning the requirement for prior approval of the protocol and the Informed Consent Form as well as continuing contact between the investigator and the IRB. Your IRB may have specific language to be included in your consent document. Check with you IRB administrator.
13.4 Financing and Insurance: Financing and insurance if not addressed in a separate agreement.
14.2 Direct Access to Source Data/Documents: The sponsor should ensure that it is specified in the protocol or other written agreement that the investigator(s)/institution(s) will permit trial-related monitoring, audits, IRB/IEC review, and regulatory inspection(s) by providing direct access to source data/documents.
Tables, figures, descriptions of special procedures, etc. (optional)